Triple therapy hope for tough esophageal cancer
NCT ID NCT07531979
First seen May 01, 2026 · Last updated May 01, 2026
Summary
This study tests a new three-drug combination for people with advanced esophageal squamous cell carcinoma (ESCC) who have not had prior treatment. The drugs include an antibody-drug conjugate (becotatug vedotin) that targets cancer cells, an immunotherapy (tislelizumab), and standard chemotherapy. The goal is to see if this combo shrinks tumors better than current treatments. About 93 adults will take part in this phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TISLELIZUMAB are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
Conditions
Explore the condition pages connected to this study.